View Older Stories View More Recent Stories

Apr 9, 2021 08:54PM Form 4 Generation Bio Co. For: Apr 07 Filed by: Atlas Venture Associates X, LLC
Apr 1, 2021 06:16PM Form 4 Ikena Oncology, Inc. For: Mar 30 Filed by: Atlas Venture Associates XI, LLC
Mar 25, 2021 08:09PM Form 3 Ikena Oncology, Inc. For: Mar 25 Filed by: Atlas Venture Fund X, L.P.
Mar 25, 2021 07:00AM Arkuda Therapeutics to Participate in Stifel's 3rd Annual CNS Day
Mar 24, 2021 09:29AM Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
Mar 24, 2021 09:29AM Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
Mar 18, 2021 05:08PM Form 4 Generation Bio Co. For: Mar 16 Filed by: Atlas Venture Fund X, L.P.
Mar 18, 2021 07:57AM Delix Therapeutics Names Mark Rus as Chief Executive Officer
Mar 16, 2021 07:38PM Form 4 Kymera Therapeutics, For: Mar 12 Filed by: Atlas Venture Associates X, LLC
Mar 16, 2021 07:00AM Remix Therapeutics Appoints Matthew R. Patterson as Executive Chairman of its Board of Directors
Mar 9, 2021 07:00AM Q32 Bio Appoints Dr. Jason Campagna as Chief Medical Officer
Mar 5, 2021 07:00AM Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at Upcoming Conferences
Feb 24, 2021 06:00AM Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
Feb 22, 2021 04:59PM Form 4 Kymera Therapeutics, For: Feb 18 Filed by: Atlas Venture Fund X, L.P.
Feb 17, 2021 08:27AM Form SC 13D/A Magenta Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 16, 2021 06:15PM Form 4 Magenta Therapeutics, For: Feb 11 Filed by: Atlas Venture Fund X, L.P.
Feb 16, 2021 05:40PM Form SC 13D/A Spero Therapeutics, Inc. Filed by: Atlas Venture Fund X, L.P.
Feb 16, 2021 05:38PM Form SC 13G Generation Bio Co. Filed by: Atlas Venture Fund X, L.P.
Feb 16, 2021 05:38PM Form SC 13G/A Akero Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 16, 2021 05:34PM Form SC 13D Gemini Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 16, 2021 05:33PM Form SC 13G Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 16, 2021 05:32PM Form SC 13G Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 11, 2021 01:48PM Form 3 Gemini Therapeutics, For: Feb 05 Filed by: Atlas Venture Associates XII, L.P.
Feb 11, 2021 11:16AM Form 13F-HR/A Atlas Venture Associates For: Dec 31
Feb 10, 2021 06:30AM Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children
Feb 8, 2021 08:00AM Monte Rosa Therapeutics Expands Senior Management Team
Feb 8, 2021 07:07AM Gemini Therapeutics (GMTX) Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration
Feb 8, 2021 07:00AM Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration
Feb 3, 2021 05:21PM Form SC 13G F-star Therapeutics, Filed by: Atlas Venture Fund VII L P
Feb 3, 2021 05:14PM Form SC 13G F-star Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Feb 3, 2021 03:50PM Form 13F-HR Atlas Venture Associates For: Dec 31
Feb 2, 2021 01:05PM Form SC 13G/A Larimar Therapeutics, Filed by: Atlas Venture Fund VII L P
Feb 2, 2021 01:03PM Form SC 13G/A Spero Therapeutics, Inc. Filed by: Atlas Venture Fund IX, L.P.
Feb 2, 2021 01:03PM Form SC 13G/A Surface Oncology, Inc. Filed by: Atlas Venture Fund IX, L.P.
Feb 2, 2021 01:02PM Form SC 13G/A Cogent Biosciences, Inc. Filed by: Atlas Venture Fund IX, L.P.
Feb 2, 2021 01:01PM Form SC 13G/A BICYCLE THERAPEUTICS Filed by: Atlas Venture Fund VIII, L.P.
Feb 2, 2021 01:01PM Form SC 13G/A Translate Bio, Inc. Filed by: Atlas Venture Fund VIII, L.P.
Feb 1, 2021 02:40PM Form 13F-HR Atlas Venture Associates For: Dec 31
Feb 1, 2021 02:40PM Form 13F-NT Atlas Venture Associates For: Dec 31
Feb 1, 2021 02:39PM Form 13F-NT ATLAS VENTURE FUND VI For: Dec 31
Feb 1, 2021 02:38PM Form 13F-NT Atlas Venture Associates For: Dec 31
Jan 25, 2021 08:00AM Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction
Jan 25, 2021 08:00AM Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction
Jan 7, 2021 07:00AM Korro Bio to Present at J.P. Morgan Healthcare Conference
Jan 7, 2021 07:00AM Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing
Jan 5, 2021 11:24AM MPM Capital Announces the Promotions of Shinichiro Fuse, Ph.D. and Kristen Laguerre to its Investment Committee
Jan 5, 2021 07:00AM Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds
Dec 28, 2020 07:40AM Form SC 13D Skillz Inc. Filed by: Atlas Venture Fund IX, L.P.
Dec 22, 2020 07:00AM Q32 Bio Appoints Experienced Biopharmaceutical Leader Mark Iwicki as Chairman of Board of Directors
Dec 21, 2020 03:35PM Form 4/A Surface Oncology, Inc. For: Dec 17 Filed by: Atlas Venture Associates IX, L.P.
View More Recent Stories View Older Stories